Raphael U. Mohr

Lobar Yttrium-90 Radioembolization with BSA-Based Dosimetry for Unresectable Hepatocellular Carcinoma: Baseline Vascularity Predicts Responders to the Combination with Targeted Therapy or Immune Checkpoint Inhibition.

Journal: Journal of hepatocellular carcinoma

Published: June 17, 2026

Impact of severe hepatic iron overload on MR and ultrasound time-harmonic elastography.

Journal: Journal of the mechanical behavior of biomedical materials

Published: October 04, 2025

Multicenter study of bleeding and thromboembolic events with durvalumab tremelimumab vs. atezolizumab and bevacizumab in advanced HCC.

Journal: JHEP reports : innovation in hepatology

Published: September 24, 2025

Protocol: Faecal microbiota transfer in liver cancer to overcome resistance to atezolizumab/bevacizumab - a multicentre, randomised, placebo-controlled, double-blind phase II trial (the FLORA trial).

Journal: BMJ open

Published: September 10, 2025

HLA-A01:01-B08:01-C*07:01 is linked to early-onset immune checkpoint inhibitor-induced myositis and myocarditis.

Journal: Journal for immunotherapy of cancer

Published: September 01, 2025

Adherence to Multidisciplinary Tumor Board Decisions Determines Long-term Survival in Patients with Hepatocellular Carcinoma.

Journal: Annals of surgery

Published: April 26, 2025

Soluble urokinase plasminogen activator receptor is a prognostic biomarker in decompensated cirrhosis.

Journal: JHEP reports : innovation in hepatology

Published: March 01, 2025

Treatment with gemcitabine/cisplatin and durvalumab for advanced biliary tract cancer - real-world data from a multicenter German patient population.

Journal: Journal of cancer research and clinical oncology

Published: February 23, 2025

miR-223 and Chromogranin A Affect Inflammatory Immune Cell Activation in Liver Metastasis of Neuroendocrine Neoplasms.

Journal: Cells

Published: December 17, 2024

Immunologic effects of locoregional therapies for unresectable hepatocellular carcinoma.

Journal: JHEP reports : innovation in hepatology

Published: October 24, 2024

Development of Liver-Heart Score for Early Detection of Myocardial Contractile Dysfunction in Cirrhosis by Strain Imaging.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: October 23, 2024

CT-guided high-dose-rate brachytherapy ablation of HCC patients with portal vein tumor thrombosis.

Journal: European radiology experimental

Published: September 26, 2024

Lobar Yttrium-90 Radioembolization with BSA-Based Dosimetry for Unresectable Hepatocellular Carcinoma: Baseline Vascularity Predicts Responders to the Combination with Targeted Therapy or Immune Checkpoint Inhibition.

Lobar Yttrium-90 Radioembolization with BSA-Based Dosimetry for Unresectable Hepatocellular Carcinoma: Baseline Vascularity Predicts Responders to the Combination with Targeted Therapy or Immune Checkpoint Inhibition.

Impact of severe hepatic iron overload on MR and ultrasound time-harmonic elastography.

Impact of severe hepatic iron overload on MR and ultrasound time-harmonic elastography.

Multicenter study of bleeding and thromboembolic events with durvalumab tremelimumab vs. atezolizumab and bevacizumab in advanced HCC.

Multicenter study of bleeding and thromboembolic events with durvalumab tremelimumab vs. atezolizumab and bevacizumab in advanced HCC.

Protocol: Faecal microbiota transfer in liver cancer to overcome resistance to atezolizumab/bevacizumab - a multicentre, randomised, placebo-controlled, double-blind phase II trial (the FLORA trial).

Protocol: Faecal microbiota transfer in liver cancer to overcome resistance to atezolizumab/bevacizumab - a multicentre, randomised, placebo-controlled, double-blind phase II trial (the FLORA trial).

HLA-A*01:01-B*08:01-C*07:01 is linked to early-onset immune checkpoint inhibitor-induced myositis and myocarditis.

HLA-A*01:01-B*08:01-C*07:01 is linked to early-onset immune checkpoint inhibitor-induced myositis and myocarditis.

Adherence to Multidisciplinary Tumor Board Decisions Determines Long-term Survival in Patients with Hepatocellular Carcinoma.

Adherence to Multidisciplinary Tumor Board Decisions Determines Long-term Survival in Patients with Hepatocellular Carcinoma.

Soluble urokinase plasminogen activator receptor is a prognostic biomarker in decompensated cirrhosis.

Soluble urokinase plasminogen activator receptor is a prognostic biomarker in decompensated cirrhosis.

Treatment with gemcitabine/cisplatin and durvalumab for advanced biliary tract cancer - real-world data from a multicenter German patient population.

Treatment with gemcitabine/cisplatin and durvalumab for advanced biliary tract cancer - real-world data from a multicenter German patient population.

miR-223 and Chromogranin A Affect Inflammatory Immune Cell Activation in Liver Metastasis of Neuroendocrine Neoplasms.

miR-223 and Chromogranin A Affect Inflammatory Immune Cell Activation in Liver Metastasis of Neuroendocrine Neoplasms.

Immunologic effects of locoregional therapies for unresectable hepatocellular carcinoma.

Immunologic effects of locoregional therapies for unresectable hepatocellular carcinoma.

Development of Liver-Heart Score for Early Detection of Myocardial Contractile Dysfunction in Cirrhosis by Strain Imaging.

Development of Liver-Heart Score for Early Detection of Myocardial Contractile Dysfunction in Cirrhosis by Strain Imaging.

CT-guided high-dose-rate brachytherapy ablation of HCC patients with portal vein tumor thrombosis.

CT-guided high-dose-rate brachytherapy ablation of HCC patients with portal vein tumor thrombosis.

HLA-A01:01-B08:01-C*07:01 is linked to early-onset immune checkpoint inhibitor-induced myositis and myocarditis.

HLA-A01:01-B08:01-C*07:01 is linked to early-onset immune checkpoint inhibitor-induced myositis and myocarditis.